UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 25, 2008
CHINA PHARMA HOLDINGS, INC.
---------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-29523 73-1564807
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification Number)
2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China,
(Address of principal executive offices)
0086-898-66811730 (China)
-------------------------
(Registrant's telephone number, including area code)
Not applicable
(Former Name or Former Address if changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
-2-
Section 2-Financial Information
Item 2.02 Results of Operations and Financial Condition.
On February 25, 2008, China Pharma Holdings, Inc., a Delaware corporation (the
"Company") issued a press release announcing, among other things, (i) new
purchase orders, totaling approximately $5,600,000, from one of its main
distributors, for its Pusen OK product, a generic version of Aleve-D, (ii)
preliminary, unaudited, revenues for the Company of approximately $33,000,000
for the fiscal year ending on December 31, 2007, and (iii) preliminary,
unaudited, revenues of approximately $4,100,000 for its Pusen OK product for the
fiscal year ending on December 31, 2007.
The press release is furnished and attached hereto as Exhibit 99.1 and is
incorporated by reference.
Section 8-Other Events
Item 8.01 Other Events.
The Information set forth above in "Item 2.02 - Results of Operations and
Financial Condition" is incorporated herein by reference.
The press release is furnished and attached hereto as Exhibit 99.1 and is
incorporated by reference.
Section 9-Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release dated February 25, 2008
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereto duly authorized.
Date: February 28, 2008 CHINA PHARMA HOLDINGS, INC.,
a Delaware corporation
By: /s/ Zhilin Li
-------------------------------------
Title: Chief Executive Officer